Provided are targeted structure-specific particulate-based delivery systems comprising: a nanoparticle; a PEG polymer coating on the surface of the nanoparticle; a targeting moiety conjugated on a surface of the nanoparticle and configured to promote specific binding to a cell surface molecule expressed by a target cell; and a biologically active agent in or on the nanoparticle, wherein the biologically active agent is selected to enhance a desired response in a target cell intracellularly or extracellularly. Methods of treating a disease or disorder administering the delivery system are contemplated.

A compound or a polymer is claimed. A first formula can be

##STR00001##

wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; T is O, N, S or NH; m equals 1 to 20; n equals 1-100; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The second formula is:

##STR00002##

wherein X is H, CH.sub.3, CN, phenyl, substituted phenyl, (CH.sub.2).sub.mZ, or phenyl(CH.sub.2).sub.mZ; and Z is CN, NH.sub.2, Thiol, OH, or CO.sub.2H. The third formula is

##STR00003##

wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently: H, CH.sub.3, OH, or a halogen.

Provided herein are fullerene compositions, and methods of preparing fullerene compositions. More particularly, the fullerene compositions include a fullerene-polymer complex having a fullerene and a non- conjugated hydrophilic or amphiphilic polymer. The non- conjugated polymer is substituted with a substituent having a functional group capable of forming intermolecular interactions with the fullerene via pi-stacking.

Compositions and methods for improved delivery of active agents to the brain are provided. The compositions typically include a nanocarrier, such as a polymeric nanoparticle, liposome, or nanolipagel or are in the form of a conjugate. The nanocarriers or conjugates typically include three components: a targeting moiety; a blood brain barrier blood-brain barrier modulator (BBB modulator), loaded into, attached to the surface of, and/or enclosed within a nanocarrier; and an additional active agent loaded into, attached to the surface of, and/or enclosed within a nanocarrier. The targeting moiety, which is typically conjugated to or otherwise dismodulator played on the surface of the nanocarrier, can be, for example, a moiety that preferentially or specifically targets brain cells or tissue, cancer cells, or a combination thereof.

The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use.

Compositions, methods, and systems for controlling crystallization of an agent are generally described. In some embodiments, an agent is crystallized in the presence of polymer matrices, such as polymer particles. The polymer matrix may influence at least a portion of the crystallization process and/or the resulting composition. In some such embodiments, the polymer matrix allows one or more aspect of the process and/or composition to be controlled and/or altered. For instance, the polymer matrix may act as a crystallization promoter and/or acceptable carriers of the crystallized agent. In certain embodiments, the polymer matrix described herein, can be used with any agent regardless of its chemical and/or physical properties.

Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.

A technique is provided which enables simple and low-cost purification of biologically active proteins by means of a conjugate of a target substance capturing molecule and a protein which comprises the amino acid sequence in SEQ ID NO:1, or a protein which comprises the amino acid sequence obtained by deleting, substituting or adding one or multiple amino acids in the amino acid sequence in SEQ ID NO: 1 and which has binding activity to a compound having OH or OR.sup.1 [R.sup.1 represents a hydrogen atom, an alkyl group or PO.sub.3H.sub.2].

Disclosed herein is a device and method for regenerating tissue using a modular scaffold having a gradient of enzymatic degradability. The disclosure further relates to scaffolds made of microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof.

Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications.